Medical Dosimetry
Volume 34, Issue 2 , Pages 133-139 , Summer 2009

Intra and Interfraction Mediastinal Nodal Region Motion: Implications for Internal Target Volume Expansions

Received 18 May 2008 ,Accepted 31 July 2008.

References 

  1. Rosenzweig KE, Sim SE, Mychalczak B, et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2001;50:681–685
  2. Emami B, Mircovic N, Scott C, et al. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: An analysis of RTOG data. Lung. Cancer. 2003;41:207–214
  3. Senan S, Burgers S, Samson MJ, et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? (Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy). Int. J. Radiat. Oncol. Biol. Phys. 2002;54:999–1006
  4. Chang DT, Zlotecki RA, Olivier KR. Re-examining the role of elective nodal irradiation: Finding ways to maximize the therapeutic ratio. Am. J. Clin. Oncol. 2005;28:597–602
  5. Jeremic B. Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in nonsmall cell lung cancer (NSCLC) (Enough to convert no-elective into elective nodal irradiation (ENI)?). Radiother. Oncol. 2004;71:123–125
  6. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer (Lung Cancer Study Group). Ann. Thorac. Surg. 1995;60(3):615–622discussion 622–3
  7. Giraud P, De Rycke Y, Lavole A, et al. Probability of mediastinal involvement in non-small-cell lung cancer: A statistical definition of the clinical target volume for 3-dimensional conformal radiotherapy?. Int. J. Radiat. Oncol. Biol. Phys. 2006;64:127–135
  8. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 1999;45:323–329
  9. Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2002;54:329–339
  10. Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: A retrospective study. Radiother. Oncol. 2003;67:275–283
  11. Jenkins P, D'Amico K, Benstead K, et al. Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART). Int. J. Radiat. Oncol. Biol. Phys. 2003;56:360–366
  12. Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003;55:110–115
  13. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis (Normal tissue complication probability). Int. J. Radiat. Oncol. Biol. Phys. 2003;55:724–735
  14. Jenkins P, Salmon C, Mannion C. Analysis of the movement of calcified lymph nodes during breathing. Int. J. Radiat. Oncol. Biol. Phys. 2005;61:329–334
  15. Wambersie A, Landberg T. Report 62 (Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU report 50)). Washington, DC: International Commission on Radiation Units and Measurements; 1999;
  16. van Sornsen de Koste JR, Lagerwaard FJ, Nijsson-Vissner MR, et al. What margins are necessary for incorporating mediastinal nodal mobility into involved-field radiotherapy for lung cancer?. Int. J. Radiat. Oncol. Biol. Phys. 2002;53:1211–1215
  17. Dawson LA, Brock KK, Kazanjian S, et al. The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001;51:1410–1421
  18. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718–1723
  19. Chapet O, Kong FM, Quint LE, et al. CT-based definition of thoracic lymph node stations: An atlas from the University of Michigan. Int. J. Radiat. Oncol. Biol. Phys. 2005;63:170–178
  20. Ekberg L, Holmberg O, Wittgren L, et al. What margins should be added to the clinical target volume in radiotherapy treatment planning for lung cancer?. Radiother. Oncol. 1998;48:71–77
  21. Seppenwoolde Y, Shirato H, Kitamura K, et al. Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2002;53:822–834
  22. Langen KM, Jones DT. Organ motion and its management. Int. J. Radiat. Oncol. Biol. Phys. 2001;50:265–278

 Work supported in part by NIH P01-CA59827.

PII: S0958-3947(08)00125-8

doi: 10.1016/j.meddos.2008.07.003

Medical Dosimetry
Volume 34, Issue 2 , Pages 133-139 , Summer 2009

Article Tools

* Image Usage & Resolution